HISA Anti-Doping and Medication Control Rule; Correction, 66705 [2022-24016]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 213 / Friday, November 4, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
prohibits management officials from
serving simultaneously with two
unaffiliated depository organizations
(i.e., depository institutions and
depository institution holding
companies), but allows for exemptions
from the prohibition in certain
circumstances. The FR L information
collection accounts for the reporting and
recordkeeping requirements associated
with implementation of DIMIA.
Legal authorization and
confidentiality: The FR L is authorized
by sections 205 and 209 of the DIMIA,
as amended.1 The FR L is required to
obtain a benefit.
Information submitted to the Board
under the reporting requirements
associated with the FR L is not
considered confidential unless an
applicant requests confidential
treatment in accordance with the
Board’s Rules Regarding Availability of
Information.2 Requests for confidential
treatment of information are reviewed
on a case-by-case basis. Information
provided to the Board under the FR L’s
reporting requirements may be
nonpublic commercial or financial
information, which is both customarily
and actually treated as private by the
respondent, which is protected from
disclosure pursuant to exemption 4 of
the Freedom of Information Act
(FOIA).3 Submissions to the Board
under these requirements may also
contain personnel and medical files the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy, which are protected
under exemption 6 of the FOIA.4
Information covered by the
recordkeeping requirements associated
with the FR L is maintained at the
relevant banking organization. The
FOIA would therefore only be
implicated if the Board obtained such
records as part of the examination or
supervision of a banking organization.
In the event the records are obtained by
the Board as part of an examination or
supervision of a financial institution,
this information would be considered
confidential pursuant to exemption 8 of
1 12 U.S.C. 3205 (exempting a director of a
diversified SLHC who is also a director of an
unaffiliated depository organization from the
DIMIA’s interlock prohibitions if both the SLHC
and the unaffiliated depository organization notify
their appropriate federal regulatory agency at least
60 days before the dual service is proposed to begin
and no agency disapproves the dual service before
the end of the 60-day period) and 3207 (authorizing
the Board to prescribe regulations carrying out the
DIMIA with respect to state member banks, BHCs,
and SLHCs).
2 12 CFR 261.17.
3 5 U.S.C. 552(b)(4).
4 5 U.S.C. 552(b)(6).
VerDate Sep<11>2014
18:12 Nov 03, 2022
Jkt 259001
66705
the FOIA, which protects information
contained in ‘‘examination, operating,
or condition reports’’ obtained in the
bank supervisory process.5 Information
covered by the FR L’s recordkeeping
requirements may also be protected
from disclosure under exemption 4 or 6
of the FOIA, depending on the contents
of the information.6
Consultation outside the agency: The
Board consulted with the Federal
Deposit Insurance Corporation and the
Office of the Comptroller of the
Currency, the other agencies with
responsibilities related to these
requirements associated with DIMIA, to
confirm alignment of the burden
estimates.
David Robbins, Executive Director, PRB
Chair
Board of Governors of the Federal Reserve
System, November 1, 2022.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
HISA Anti-Doping and Medication
Control Rule; Correction
[FR Doc. 2022–24029 Filed 11–3–22; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL TRADE COMMISSION
SES Performance Review Board
Federal Trade Commission.
Notice.
AGENCY:
ACTION:
Notice is hereby given of the
appointment of members to the FTC
Performance Review Board.
FOR FURTHER INFORMATION CONTACT:
Monique Fortenberry, Acting Chief
Human Capital Officer, 600
Pennsylvania Avenue NW, Washington,
DC 20580, (202) 326–2017.
SUPPLEMENTARY INFORMATION:
Publication of the Performance Review
Board (PRB) membership is required by
5 U.S.C. 4314(c)(4). The PRB reviews
and evaluates the initial appraisal of a
senior executive’s performance by the
supervisor, and makes
recommendations regarding
performance ratings, performance
awards, and pay-for-performance pay
adjustments to the Chairman.
The following individuals have been
designated to serve on the Commission’s
Performance Review Board:
Reilly James Dolan, Principal Deputy
General Counsel
Monique Fortenberry, Acting Chief
Human Capital Officer and Deputy
Executive Director
Tara Koslov, Deputy Director, Bureau of
Competition
David Rebich, Deputy Executive
Director
SUMMARY:
55
65
PO 00000
U.S.C. 552(b)(8).
U.S.C. 552(b)(4) and (6).
Frm 00067
Fmt 4703
Sfmt 4703
Monica Vaca, Deputy Director, Bureau
of Consumer Protection
Michael Vita, Deputy Director, Bureau
of Economics
By direction of the Commission.
April J. Tabor,
Secretary.
[FR Doc. 2022–24043 Filed 11–3–22; 8:45 am]
BILLING CODE 6750–01–P
FEDERAL TRADE COMMISSION
[File No. P222100]
AGENCY:
Federal Trade Commission.
Notice of Horseracing Integrity
and Safety Authority (HISA) proposed
rule; correction.
ACTION:
The Federal Trade
Commission (‘‘Commission’’) published
a document in the Federal Register of
October 28, 2022, concerning the AntiDoping and Medication Control
proposed rule submitted by the
Horseracing Integrity and Safety
Authority. The Authority alerted the
Commission that its submission
contained an incorrect number. The
Commission is issuing this correction to
reflect the corrected number.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Austin King, Associate General Counsel
for Rulemaking, 202–326–3166, aking3@
ftc.gov, Office of the General Counsel,
Federal Trade Commission, 600
Pennsylvania Avenue NW, Washington,
DC 20580.
SUPPLEMENTARY INFORMATION:
Correction
In FR Doc. 2022–22970 appearing at
87 FR 65292 in the Federal Register of
Friday, October 28, 2022, in the table on
page 65365, in the entry for
‘‘ketoprofen,’’ change the first sentence
of the final column, which currently
reads [4 ng/mL in serum or plasma.], to
read [2 ng/mL in serum or plasma.],
which is the amount the Authority
intended to submit but did not because
of a typographical error.
Dated: October 31, 2022.
April J. Tabor,
Secretary.
[FR Doc. 2022–24016 Filed 11–3–22; 8:45 am]
BILLING CODE 6750–01–P
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 87, Number 213 (Friday, November 4, 2022)]
[Notices]
[Page 66705]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24016]
-----------------------------------------------------------------------
FEDERAL TRADE COMMISSION
[File No. P222100]
HISA Anti-Doping and Medication Control Rule; Correction
AGENCY: Federal Trade Commission.
ACTION: Notice of Horseracing Integrity and Safety Authority (HISA)
proposed rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Federal Trade Commission (``Commission'') published a
document in the Federal Register of October 28, 2022, concerning the
Anti-Doping and Medication Control proposed rule submitted by the
Horseracing Integrity and Safety Authority. The Authority alerted the
Commission that its submission contained an incorrect number. The
Commission is issuing this correction to reflect the corrected number.
FOR FURTHER INFORMATION CONTACT: Austin King, Associate General Counsel
for Rulemaking, 202-326-3166, [email protected], Office of the General
Counsel, Federal Trade Commission, 600 Pennsylvania Avenue NW,
Washington, DC 20580.
SUPPLEMENTARY INFORMATION:
Correction
In FR Doc. 2022-22970 appearing at 87 FR 65292 in the Federal
Register of Friday, October 28, 2022, in the table on page 65365, in
the entry for ``ketoprofen,'' change the first sentence of the final
column, which currently reads [4 ng/mL in serum or plasma.], to read [2
ng/mL in serum or plasma.], which is the amount the Authority intended
to submit but did not because of a typographical error.
Dated: October 31, 2022.
April J. Tabor,
Secretary.
[FR Doc. 2022-24016 Filed 11-3-22; 8:45 am]
BILLING CODE 6750-01-P
